vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$13.13 USD
-0.22 (-1.65%)
Updated Sep 27, 2024 02:23 PM ET
After-Market: $13.86 +0.73 (5.56%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.13 USD
-0.22 (-1.65%)
Updated Sep 27, 2024 02:23 PM ET
After-Market: $13.86 +0.73 (5.56%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
by Zacks Equity Research
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
Why vTv Therapeutics (VTVT) Could Be Positioned for a Surge
by Zacks Equity Research
vTv Therapeutics (VTVT) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
vTv Therapeutics Inc. (VTVT) saw its shares rise almost 7% in the last trading session.